Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer PatientsCompleted
NCT00129896Phase 1, Phase 2Updated Mar 6, 2023
Sponsor: Spanish Breast Cancer Research Group
Breast Cancer
Spain
Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target TherapyUnknown
NCT05754502N/AUpdated Mar 3, 2023
Sponsor: Consorzio Oncotech
Breast Cancer
Italy
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).Terminated
NCT04236141Phase 3Updated Mar 3, 2023
Sponsor: Hoffmann-La Roche
Diffuse, Large B-Cell, Lymphoma
China
Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)Completed
NCT02073279Phase 3Updated Mar 1, 2023
Sponsor: Hoffmann-La Roche
Neuromyelitis Optica (NMO) · NMO Spectrum Disorder (NMOSD)
United States, Bulgaria, Canada, Croatia, Georgia +10 more
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationCompleted
NCT04615325Phase 1Updated Mar 1, 2023
Sponsor: Hoffmann-La Roche
Geographic Atrophy
United States
A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple MyelomaCompleted
NCT03312530Phase 1, Phase 2Updated Feb 28, 2023
Sponsor: Hoffmann-La Roche
Multiple Myeloma
Czechia, Denmark, France, Germany, Netherlands +4 more
Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid TumorsTerminated
NCT03386721Phase 2Updated Feb 21, 2023
Sponsor: Hoffmann-La Roche
Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
United States, Belgium, France, Germany, Israel +10 more
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompleted
NCT03038100Phase 3Updated Feb 17, 2023
Sponsor: Hoffmann-La Roche
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
United States, Australia, Austria, Belgium, Brazil +17 more
Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)Completed
NCT03063762Phase 1Updated Feb 17, 2023
Sponsor: Hoffmann-La Roche
Renal Cell Carcinoma
United States, Canada, Denmark, France, Germany +4 more
A Study of Gantenerumab in Participants With Mild Alzheimer DiseaseCompleted
NCT02051608Phase 3Updated Feb 10, 2023
Sponsor: Hoffmann-La Roche
Alzheimer's Disease
United States, Argentina, Australia, Belgium, Bulgaria +17 more
Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRICompleted
NCT03438357N/AUpdated Feb 8, 2023
Sponsor: Centre Hospitalier Universitaire de Nīmes
Multiple Sclerosis · Clinically Isolated Syndrome
France
Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]Completed
NCT04059887Phase 4Updated Feb 8, 2023
Sponsor: Chonnam National University Hospital
Lung Neoplasm Malignant
South Korea
Kidney AI-enabled Care TransformationWithdrawn
NCT05056909NAUpdated Feb 2, 2023
Sponsor: Medical University of Graz
Chronic Kidney Diseases
Italy, United Kingdom
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)Completed
NCT04436744Phase 2Updated Feb 2, 2023
Sponsor: Hoffmann-La Roche
Early Breast Cancer
United States, Australia, Brazil, Germany, Hungary +6 more
RLY-1971 in Subjects With Advanced or Metastatic Solid TumorsCompleted
NCT04252339Phase 1Updated Jan 31, 2023
Sponsor: Hoffmann-La Roche
Solid Tumor, Unspecified, Adult
United States
Therapeutic Option for Hepatitis B and C: a French CohortUnknown
NCT01953458N/AUpdated Jan 31, 2023
Sponsor: ANRS, Emerging Infectious Diseases
Viral Hepatitis B · Viral Hepatitis C
France
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)Completed
NCT02420821Phase 3Updated Jan 30, 2023
Sponsor: Hoffmann-La Roche
Renal Cell Carcinoma
United States, Australia, Bosnia and Herzegovina, Brazil, Canada +16 more
A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)Completed
NCT02797769N/AUpdated Jan 25, 2023
Sponsor: Hoffmann-La Roche
Rheumatoid Arthritis
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLLCompleted
NCT02758665Phase 2Updated Jan 17, 2023
Sponsor: University of Ulm
Leukemia, Lymphocytic, Chronic
Germany
Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)Completed
NCT03829306N/AUpdated Jan 13, 2023
Sponsor: Spanish Breast Cancer Research Group
Advanced Breast Cancer
Spain
Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic LeukemiaCompleted
NCT03374137N/AUpdated Jan 12, 2023
Sponsor: Hoffmann-La Roche
Chronic Lymphocytic Leukemia · Follicular Lymphoma
South Korea
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia ACompleted
NCT03020160Phase 3Updated Jan 11, 2023
Sponsor: Hoffmann-La Roche
Hemophilia A
United States, Australia, Belgium, Japan, Poland +1 more
An Observational Study of Kadcyla Safety in Breast CancerCompleted
NCT02305641N/AUpdated Jan 11, 2023
Sponsor: Hoffmann-La Roche
Breast Cancer
South Korea
A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing ChemotherapyCompleted
NCT02813785Phase 3Updated Jan 10, 2023
Sponsor: Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
China, Malaysia, Singapore, South Korea, Thailand
Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)Completed
NCT02303119Phase 3Updated Jan 10, 2023
Sponsor: The Lymphoma Academic Research Organisation
Follicular Lymphoma
France

Previous page Next page